PGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Precigen Inc (PGEN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive analyst ratings, and promising product traction in the market outweigh the lack of recent news and hedge fund selling trends. While technical indicators are neutral to slightly bullish, the long-term potential driven by PAPZIMEOS sales and improving financials make this a solid investment opportunity.
The MACD is above 0 and positively contracting, indicating a slightly bullish trend. RSI is neutral at 48.226, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at $3.83, and resistance is at $4.304. The stock is trading near support, providing a potential entry point.
Analysts have raised price targets to $9 and $10, citing strong early commercial traction for PAPZIMEOS and expected Q1 sales exceeding $18M.
Financials show significant YoY revenue growth (283.61%) and gross margin improvement (3595.45%).
PAPZIMEOS is well-positioned as the first and only approved therapy in its market, with broad patient engagement and solid reimbursement access.
Hedge funds are selling, with an 801.59% increase in selling activity over the last quarter.
No recent news or congress trading data to provide additional sentiment or validation.
In Q4 2025, revenue increased by 283.61% YoY to $4.57M. Net income improved by 19.14% YoY but remains negative at -$23.5M. EPS remained flat at -0.07. Gross margin surged to 65.04%, up 3595.45% YoY, indicating improved operational efficiency.
Analysts from Citizens and H.C. Wainwright have raised price targets to $9 and $10, respectively, and maintained Outperform/Buy ratings. They highlight strong early sales metrics for PAPZIMEOS and reaffirmed funding through cash flow break-even.
